given
lethal
avian
influenza
virus
aiv
recur
spread
poultri
human
effect
vaccin
virus
may
need
prevent
pandem
gener
experiment
vaccin
vector
base
recombin
vesicular
stomat
viru
vsv
express
hemagglutinin
viru
isol
ha
gene
express
either
attenu
wildtyp
vsv
vector
singlecycl
vector
contain
delet
vsv
g
gene
found
vector
induc
potent
neutral
antibodi
titer
homolog
antigen
heterolog
virus
isol
vaccin
mice
combin
prime
primeboost
vector
provid
longlast
protect
month
challeng
aiv
even
anim
receiv
singl
dose
singlecycl
vaccin
data
indic
recombin
promis
vaccin
candid
pandem
influenza
influenza
pandem
occur
kill
million
peopl
worldwid
pandem
aris
novel
influenza
subtyp
emerg
spread
human
gener
avian
reservoir
wright
webster
virus
influenza
genu
subdivid
basi
antigen
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
current
known
type
ha
na
fouchier
et
al
wright
webster
outbreak
subtyp
avian
influenza
viru
aiv
occur
hong
kong
poultri
human
first
time
subtyp
known
caus
diseas
human
virus
emerg
continu
caus
diseas
poultri
human
present
day
gillimross
sinc
least
peopl
infect
virus
associ
mortal
rate
http
wwwwhointcsrdiseaseavianinfluenza
despit
unusu
high
mortal
rate
human
outbreak
probabl
contain
current
strain
spread
effici
person
person
ungchusak
et
al
high
mortal
rate
continu
spread
trigger
world
health
organ
us
center
diseas
control
prevent
issu
warn
possibl
pandem
strain
emerg
sinc
alreadi
split
numer
sublineag
clade
chen
et
al
illustr
rapid
evolut
viru
abil
subtyp
aiv
infect
human
emphas
need
vaccin
protect
aiv
infect
compar
human
influenza
vaccin
target
epidem
influenza
develop
aiv
vaccin
problemat
tradit
influenza
vaccin
prepar
grow
attenu
reassort
virus
embryon
chicken
egg
attenu
virus
encod
ha
na
protein
predict
present
upcom
season
epidem
virus
howev
aiv
greatest
potenti
public
health
threat
highli
pathogen
avian
influenza
hpai
virus
pathogen
grow
effici
egg
requir
costli
level
biocontain
newli
emerg
viru
might
spread
rapidli
popul
long
leadtim
requir
tradit
vaccin
product
also
major
concern
effort
creat
aiv
vaccin
mani
group
explor
new
approach
gener
vaccin
protect
strain
review
gillimross
subbarao
horimoto
kawaoka
inactiv
live
attenu
aiv
vaccin
develop
strategi
inactiv
subvirion
recombin
subunit
dna
vaccin
investig
viru
vector
adenoviru
newcastl
diseas
viru
vector
encod
influenza
antigen
also
explor
potenti
aiv
vaccin
avian
human
use
ge
et
al
horimoto
kawaoka
park
et
al
veit
et
al
experiment
viru
vaccin
vector
base
attenu
vesicular
stomat
virus
vsv
express
foreign
viral
antigen
develop
brandsma
et
al
daddariodicaprio
et
al
egan
et
al
garbutt
et
al
jone
et
al
kahn
et
al
kapadia
et
al
publicov
ramsburg
rose
ramsburg
et
al
reuter
et
al
robert
et
al
robert
et
al
robert
et
al
schlereth
et
al
schnell
et
al
vector
protect
anim
numer
viral
challeng
initi
studi
vsv
vaccin
vector
show
vsv
express
ha
protein
wsn
strain
influenza
elicit
high
neutral
antibodi
titer
mice
protect
mice
challeng
lethal
dose
wsn
viru
robert
et
al
robert
et
al
vsv
versatil
vaccin
vector
mani
reason
includ
fact
exposur
seroposit
vsv
neglig
human
popul
addit
replic
sole
cytoplasm
undergo
recombin
gener
dna
intermedi
might
integr
host
genom
rose
whitt
vsv
rel
simpl
genom
accommod
least
kilobas
foreign
gene
highli
express
infect
cell
moreov
vsv
effect
administ
intranas
easili
manufactur
larg
scale
cell
line
alreadi
approv
vaccin
product
also
highli
attenu
mutant
vsv
well
replic
defect
singlecycl
vsv
vector
still
gener
potent
immun
respons
publicov
ramsburg
rose
publicov
ramsburg
rose
robert
et
al
present
studi
gener
replic
singlecycl
vsv
vector
express
ha
gene
deriv
prototyp
aiv
ahong
hk
origin
isol
lethal
human
infect
subbarao
et
al
assess
efficaci
vector
examin
abil
vsv
express
ha
induc
neutral
antibodi
respons
homolog
viru
addit
determin
vaccin
could
elicit
crossneutr
antibodi
titer
distantli
relat
virus
vector
without
boost
abl
induc
neutral
antibodi
respons
virus
test
furthermor
respons
protect
mous
model
aiv
challeng
protect
achiev
singl
dose
vaccin
longlast
order
gener
vsvbase
vaccin
vector
avian
influenza
incorpor
ha
gene
aiv
strain
three
differ
recombin
vsv
rvsv
vector
shown
fig
two
replic
compet
vector
ha
gene
insert
fifth
genom
posit
downstream
vsv
g
gene
one
vector
ha
fig
contain
vsv
g
indiana
serotyp
allow
effect
boost
prime
vector
contain
indiana
g
protein
boost
vector
substitut
gene
vsv
g
gene
new
jersey
serotyp
ha
fig
prime
vsv
vector
preclud
effect
boost
vector
high
level
neutral
antibodi
gener
vsv
g
protein
addit
gener
singlecycl
vector
g
gene
delet
ha
fig
vector
propag
complement
cell
line
express
vsv
g
schnell
et
al
howev
spread
anim
beyond
initi
infect
cell
encod
vsv
g
protein
singlecycl
vector
elimin
concern
pathogenesi
vsv
recombin
determin
ha
gene
express
recombin
vector
western
blot
analysi
perform
whole
cell
extract
infect
cell
protein
mobil
expect
ha
protein
ha
cleav
form
ha
ha
accumul
cell
infect
three
vector
cell
infect
parent
wildtyp
wt
viru
fig
left
panel
blot
strip
reprob
antivsv
indiana
antibodi
vsv
protein
detect
infect
cell
except
g
protein
cell
infect
singlecycl
vector
ha
encod
vsv
g
cell
infect
ha
nj
g
protein
detect
well
antivsv
indiana
serum
fig
left
panel
trace
cross
reactiv
nj
g
protein
detect
blot
virion
protein
fig
right
panel
determin
ha
protein
incorpor
recombin
vsv
virion
purifi
virion
ultracentrifug
perform
western
blot
analysi
virion
protein
antiha
antibodi
figur
right
panel
show
cleav
form
ha
ha
incorpor
virion
rvsv
express
ha
wt
virion
presenc
littl
ha
recombin
virion
expect
ha
cleav
reach
cell
surfac
wright
webster
vsv
bud
occur
rose
whitt
reprob
blot
antivsv
serum
show
expect
vsv
protein
also
present
virion
fig
right
panel
evalu
abil
rvsv
vaccin
vector
gener
neutral
antibodi
avian
influenza
mice
prime
intramuscularli
im
intranas
ha
im
ha
half
mice
group
boost
one
month
later
respect
rout
g
serotyp
switch
vector
ha
rvsv
vector
express
unrel
protein
use
neg
control
vector
serum
antibodi
respons
homolog
aiv
analyz
individu
mice
variou
time
postprim
fig
use
aiv
microneutr
assay
measur
neutral
infect
suguitan
et
al
singl
dose
either
ha
singlecycl
vector
ha
elicit
neutral
antibodi
titer
homolog
viru
earli
month
postprim
data
shown
peak
month
postprim
fig
gray
bar
antibodi
persist
month
postprim
fig
black
bar
neutral
titer
enhanc
substanti
boost
anim
vaccin
im
prime
anim
vaccin
higher
titer
anim
vaccin
im
fig
boost
vaccine
less
effect
fig
perhap
presenc
higher
initi
level
neutral
antibodi
direct
ha
prime
frequenc
antigen
chang
drift
influenza
virus
import
determin
vaccin
candid
gener
neutral
antibodi
aiv
clade
within
subtyp
therefor
examin
abil
rvsv
gener
crossneutr
antibodi
respons
heterolog
aiv
avietnam
virus
clade
emerg
year
isol
strain
isol
geograph
distinct
area
found
singl
im
dose
either
ha
ha
elicit
detect
crossneutr
antibodi
clade
viru
fig
gray
bar
clade
viru
fig
black
bar
anim
gener
boost
anim
substanti
increas
crossneutr
antibodi
titer
aiv
fig
also
examin
whether
vaccin
vector
could
induc
crossneutr
antibodi
respons
anoth
close
relat
clade
viru
ahong
highli
pathogen
avian
influenza
hpai
viru
much
pathogen
mice
homolog
strain
therefor
suitabl
use
subsequ
challeng
studi
singl
vaccin
elicit
substanti
crossneutr
antibodi
titer
individu
mice
enhanc
boost
fig
tabl
respons
gener
fig
greater
seen
fig
lower
rais
homolog
clade
strain
fig
sever
experiment
vaccin
vector
express
ha
show
promis
knowledg
studi
examin
longterm
efficaci
vaccin
mammalian
model
mice
vaccin
rvsv
express
ha
challeng
hpai
month
postprim
month
postboost
anim
boost
mice
challeng
mice
immunogen
vaccin
vector
determin
fig
except
mice
die
prior
challeng
mice
vaccin
neg
control
viru
vsvgag
lost
approxim
bodi
weight
within
first
week
postchalleng
fig
mice
die
day
postchalleng
control
mice
fig
tabl
mice
vaccin
combin
prime
boost
vector
includ
mice
receiv
singl
vaccin
dose
either
replic
ha
singlecycl
vector
ha
remain
healthi
throughout
durat
experi
exhibit
weight
loss
sign
diseas
fig
tabl
surviv
highli
signific
vaccin
mice
compar
vsvgag
vaccin
control
mice
pvalu
rang
tabl
mean
geometr
titer
challeng
viru
vaccin
anim
rang
tabl
even
anim
lowest
titer
month
postprim
fig
tabl
complet
protect
challeng
month
postprim
fig
tabl
complet
protect
achiev
im
fig
vaccin
fig
highli
pathogen
natur
recent
emerg
virus
continu
spread
poultri
popul
high
mortal
caus
human
gener
major
concern
possibl
aiv
pandem
concern
led
new
effort
develop
aiv
vaccin
includ
develop
nontradit
method
vsv
vaccin
vector
express
foreign
antigen
capabl
provid
protect
number
respiratori
viral
diseas
sar
kapadia
et
al
influenza
robert
et
al
robert
et
al
rsv
kahn
et
al
vsv
vector
shown
promis
aid
vaccin
monkey
model
egan
et
al
ramsburg
et
al
highli
attenu
vsv
express
hiv
antigen
soon
enter
clinic
trial
experiment
aid
vaccin
gener
experiment
vsvbase
aiv
vaccin
insert
ha
gene
strain
recombin
wt
singlecycl
vsv
vector
chose
ha
protein
major
correl
protect
influenza
antibodi
surfac
glycoprotein
primarili
ha
wright
webster
recov
rvsv
express
fulllength
cleav
ha
infect
cell
cleav
ha
ha
incorpor
rvsv
virion
fig
assess
serolog
respons
vaccin
mice
im
inocul
mice
receiv
singl
dose
vaccin
other
receiv
boost
serotyp
switch
vector
found
high
neutral
antibodi
titer
present
mice
receiv
combin
rvsv
vector
either
rout
titer
peak
month
postprim
still
high
month
postprim
fig
influenza
virus
undergo
frequent
mutat
import
vaccin
intend
pandem
influenza
abl
crossneutr
antigen
distinguish
aiv
subtyp
found
rvsv
vector
elicit
crossneutr
antibodi
three
distinct
virus
fig
tabl
level
suggest
protect
heterolog
strain
vaccin
mice
challeng
month
postprim
lethal
dose
hpai
vaccine
includ
receiv
singl
dose
singlecycl
vector
surviv
challeng
protect
aivassoci
diseas
fig
tabl
control
mice
die
within
day
postchalleng
serolog
data
correl
complet
protect
pulmonari
replic
seen
previou
studi
administr
two
dose
coldadapt
ca
vaccin
suguitan
et
al
titer
induc
rvsv
vaccin
higher
achiev
two
dose
ca
vaccin
suguitan
et
al
moreov
vaccin
rvsv
express
ha
wsn
strain
show
rvsv
vaccin
influenza
complet
prevent
influenza
replic
lung
follow
challeng
robert
et
al
prevent
aivassoci
weight
loss
high
neutral
antibodi
titer
rvsv
vaccin
studi
suggest
protect
replic
direct
assay
viru
replic
possibl
facil
experi
carri
regul
prevent
remov
sampl
assay
outsid
facil
replic
therefor
address
futur
studi
vsvbase
aiv
vaccin
candid
potenti
advantag
vaccin
candid
includ
eas
deliveri
intranas
rout
neglig
vsv
seroposit
human
product
cell
line
alreadi
approv
manufactur
human
vaccin
rather
egg
vsvbase
vaccin
also
elimin
safeti
concern
grow
aivbas
vaccin
risk
exposur
accident
spread
product
furthermor
vsv
vector
effect
rel
low
dose
typic
effect
seen
singl
vaccin
requir
use
adjuv
although
wt
vsv
caus
neurolog
diseas
natur
host
anim
neuroinvas
follow
intranas
inocul
mice
sabin
olitski
safeti
concern
use
replic
compet
vsv
vector
therefor
address
prototyp
attenu
vsv
vector
neuroinvas
nonhuman
primat
intranas
administr
furthermor
highli
attenu
live
vsv
vector
gener
lack
neurovirul
nonhuman
primat
follow
direct
intracrani
thalam
inocul
also
vector
describ
lack
vsv
g
gene
elimin
concern
neurovirul
replic
singl
cycl
anoth
potenti
safeti
concern
aris
fact
ha
protein
incorpor
vsv
virion
howev
unabl
demonstr
infect
virus
due
ha
protein
vector
express
ha
influenza
viru
requir
receptordestroy
activ
na
propag
lamb
krug
absenc
influenza
na
gene
construct
also
predict
lack
pathogen
due
ha
incorpor
virion
current
gener
vsv
recombin
express
solubl
secret
form
ha
could
incorpor
virion
membran
recombin
would
provid
addit
safeti
factor
could
potenti
effect
gener
neutral
antibodi
influenza
vsvbase
vector
excel
potenti
vaccin
protect
pandem
aiv
warrant
develop
bhkg
schnell
et
al
cell
grown
dulbecco
modifi
essenti
medium
dmem
contain
fetal
bovin
serum
fb
penstrep
bhkg
cell
mainten
media
supplement
ngml
tetracyclin
tet
mdck
cell
propag
membsa
minim
essenti
medium
mem
supplement
bovin
serum
albumin
bsa
penstrep
recombin
vsv
grown
titrat
plaqu
assay
bhkg
cell
previous
describ
lawson
et
al
schnell
et
al
ha
stock
use
vaccin
resuspend
pb
centrifug
infect
cell
media
rpm
beckman
rotor
g
h
neg
control
rvsv
vector
vsvgag
contain
siv
gag
gene
fifth
vsv
genom
posit
describ
previous
aiv
ahong
ahong
kindli
provid
dr
nanci
cox
alexand
klimov
influenza
branch
center
diseas
control
prevent
atlanta
ga
propag
allanto
caviti
specif
pathogenfre
egg
describ
previous
suguitan
et
al
use
mous
challeng
experi
grown
titrat
plaqu
assay
mdck
cell
media
supplement
tpcktreat
trypsin
ha
gene
access
kindli
provid
kawaoka
univers
wisconsin
madison
wi
amplifi
pcr
primer
introduc
xmai
xhoi
site
underlin
respect
clone
xmaixhoi
digest
pbluescript
ii
sk
gener
ha
gene
amplifi
pcr
use
primer
introduc
xhoi
nhei
site
underlin
respect
xhoinhei
digest
pcr
product
clone
xhoi
nhei
site
schnell
et
al
pvsvnjgxn
vector
gener
ha
ha
respect
vector
gener
replac
ha
gene
awsn
strain
robert
et
al
ha
pcr
product
recombin
vsv
ha
ha
recov
use
plasmid
previous
describ
lawson
et
al
briefli
cell
infect
polymeras
express
vaccinia
viru
fuerst
et
al
moi
h
postinfect
hpi
cell
transfect
appropri
ha
plasmid
plu
support
plasmid
pbsn
pbsp
pbsg
pbsl
cell
cultur
media
collect
filter
filter
passag
onto
cell
h
posttransfect
cpe
observ
cultur
media
filter
filter
plaqu
purifi
use
grow
viru
stock
growth
recoveri
ha
achiev
complement
bhkg
cell
express
vsv
g
schnell
et
al
order
optim
titer
either
bhkg
cell
cell
transient
express
g
pcaggsg
publicov
ramsburg
rose
use
cell
cell
infect
indic
viru
hpi
cell
wash
twice
icecold
pb
incub
lysi
buffer
deoxychol
mm
edta
mm
trishcl
ph
min
ice
ii
vsv
virionsth
cultur
media
infect
cell
exhibit
cpe
clarifi
low
speed
centrifug
layer
top
sucros
te
ph
subject
ultracentrifug
beckman
rotor
rpm
g
h
pellet
resuspend
lysi
buffer
iii
sdspagewestern
blotinfect
cell
virion
lysat
combin
sdssampl
buffer
mm
trishcl
ph
glycerol
vv
sd
bromophenol
blue
vv
subject
sdspage
acrylamid
gel
protein
transfer
nitrocellulos
semidri
transfer
apparatu
biorad
laboratori
inc
hercul
ca
accord
manufactur
instruct
blot
incub
overnight
pbstmilk
pb
contain
pbst
nonfat
milk
dilut
polyclon
antiinfluenza
viru
ha
ahong
sheep
antiserum
pbstmilk
h
room
temperatur
antibodi
obtain
nih
biodefens
emerg
infect
research
repositori
niaid
nih
wash
time
pbst
blot
incub
donkey
antisheep
igg
conjug
hrp
santa
cruz
biotechnolog
santa
cruz
ca
dilut
pbstmilk
h
blot
wash
incub
mixtur
ecl
western
blot
detect
reagent
ge
healthcar
piscataway
nj
chemiluminesc
detect
use
imag
system
fujifilm
blot
incub
strip
buffer
mm
trishcl
ph
sd
mm
min
wash
sever
time
pb
probe
vsv
protein
describ
use
rabbit
polyclon
antivsv
antibodi
dilut
mous
antirabbit
igg
conjug
hrp
pierc
biotechnolog
rockford
il
dilut
yale
univers
institut
anim
care
use
committe
approv
vaccin
six
eight
week
old
balbc
femal
mice
charl
river
laboratori
wilmington
prime
intramuscularli
im
intranas
contain
plaqu
form
unit
pfu
ha
dmem
approxim
pfu
ha
pb
mice
vaccin
lightli
anesthet
isofluran
vv
baxter
deerfield
il
propylen
glycol
prior
vaccin
month
postprim
half
mice
boost
im
pfu
ha
dmem
describ
ha
neutral
antibodi
titer
determin
previous
describ
suguitan
et
al
briefli
serum
obtain
vaccin
mice
heat
inactiv
min
subject
serial
dilut
start
dilut
equal
volum
tcid
indic
viru
dilut
serum
combin
incub
room
temperatur
h
ad
mdck
cell
quadrupl
neutral
titer
repres
reciproc
dilut
neutral
defin
absenc
cpe
day
sampl
display
neutral
activ
arbitrarili
given
valu
assay
conduct
use
enhanc
contain
procedur
laboratori
approv
use
us
depart
agricultur
center
diseas
control
prevent
month
postprim
vaccin
mice
challeng
ld
pfu
membsa
ld
determin
reed
muench
method
reed
muench
mice
weigh
daili
analyz
diseas
day
mice
exhibit
sever
morbid
human
euthan
data
shown
averag
percent
origin
prechalleng
weight
challeng
perform
use
contain
procedur
approv
anim
use
protocol
accord
guidelin
canadian
council
anim
care
panel
prepar
cell
infect
indic
virus
virion
purifi
infect
cell
supernat
right
panel
subject
analysi
sdspage
western
blot
analys
perform
use
antibodi
specif
b
ha
c
vsv
antivsv
blot
c
blot
b
strip
reprob
antivsv
indiana
antibodi
fulllength
ha
cleav
isoform
ha
ha
ha
well
vsv
protein
g
n
p
indic
arrow
mice
vaccin
im
ha
ha
neg
control
vector
vsvgag
gag
month
postprim
anim
boost
ha
indic
variou
time
postprim
sera
individu
mice
analyz
neutral
antibodi
respons
homolog
aiv
strain
mo
postprim
gray
black
bar
respect
bar
repres
neutral
antibodi
titer
individu
mous
determin
inhibit
cpe
microneutr
assay
mice
vaccin
im
ha
ha
neg
control
vector
vsvgag
gag
month
postprim
anim
boost
ha
indic
variou
time
postprim
sera
individu
mice
analyz
neutral
antibodi
respons
heterolog
strain
gray
bar
black
bar
mo
postprim
b
mo
postprim
bar
repres
neutral
antibodi
titer
individu
mous
determin
inhibit
cpe
microneutr
assay
dot
horizont
line
valu
repres
limit
detect
assay
valu
consid
neg
asterisk
indic
mice
challeng
fig
die
unrel
caus
eg
anesthesia
prior
challeng
balbc
mice
vaccin
im
b
ha
squar
respect
ha
triangl
vsvgag
circl
month
postprim
mice
boost
ha
solid
squar
b
solid
triangl
b
month
postprim
mice
challeng
ld
naiv
mice
also
challeng
gray
diamond
dash
line
comparison
group
naiv
mice
depict
panel
bodi
weight
surviv
assess
daili
termin
analysi
due
death
anim
tabl
serolog
respons
protect
challeng
virolog
author
manuscript
avail
pmc
may
